Methotrexate in resistant juvenile rheumatoid arthritis: Results of the U.S.A.–U.S.S.R. double-blind, placebo-controlled trial

New England Journal of Medicine

Volumn 326, Issue 16, 1992, Pages 1043-1049

  Giannini, Edward H ^a   Brewer, Earl J ^b   Kuzmina, Nina ^c   Shaikov, Alexander ^c   Maximov, Alexei ^c   Vorontsov, Igor ^d   Fink, Chester W ^e   Newman, Arthur J ^f   Cassidy, James T ^g   Zemel, Lawrence S ^h  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^d SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g UNIVERSITY OF MISSOURI   (United States)

^h Farmington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLAMINE; PLACEBO; PREDNISONE; STEROID;

ADOLESCENT; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG USE; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; JOINT LIMITATION; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0026609159     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199204163261602     Document Type: Article

References (36)

1. Towner S.R., Michet C.J. Jr., O#x0027;Fallon W.M., Nelson A.M. The epidemiology of juvenile arthritis in Rochester, Minnesota 1960–1979. Arthritis Rheum 1983; 26:1208-1213
2. Petty R.E., Malleson P. Epidemiology of juvenile rheumatoid arthritis. World Pediatrics Child Care 1987; 3:205-210
3. Cassidy J.T., Petty R.E. Textbook of pediatric rheumatology. 2nd ed. New York: Churchill Livingstone, 1990: 114.
4. Williams H.J., Willkens R.F., Samuelson C.O. Jr., et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985; 28: 721-30.
5. Weinblatt M.E., Coblyn J.S., Fox D.A., et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:818-822
6. Kremer J.M., Lee J.K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986:29:822-831
7. Weinblatt M.E., Trentham D.E., Fraser P.A., et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31:167-175
8. Kremer J.M., Lee J.K. A long-term prospective study of the use of methotrexate in rheumatoid arthritis: update after a mean of fifty-three months. Arthritis Rheum 1988; 31:577-584
9. Alarcon G.S., Tracy I.C., Blackburn W.D. Jr. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32:671-676
10. Wolfe F., Hawley D.J., Cathey M.A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17:994-1002.
11. Mielants H., Veys E.M., van der Straeten C., Ackerman C., Goemaere S. The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. J Rheumatol 1991; 18:978-983
12. Truckenbrodt H., Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 1986; 29:801-807
13. Speckmaier M., Findeisen J., Woo P., et al. Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 1989; 7:647-650
14. Wallace C.A., Bleyer W.A., Sherry D.D., Salmonson K.L., Wedgwood R.J. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32:677-681
15. Rose C.D., Singsen B.H., Eichenfield A.H., Goldsmith D.P., Athreya B.H. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1990; 177:653-659
16. Martini A., Ravelli A., Viola S., Burgio R.G. Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis. J Pediatr 1991; 119:333-334
17. Halle F., Prieur A.M. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991; 9:297-302.
18. Baum J., Alekseev L.S., Brewer E.J. Jr., Dolgopolova A.V., Mudholkar G.S., Patel K. Juvenile rheumatoid arthritis: a comparison of patients from the USSR and USA. Arthritis Rheum 1980; 23:977-984
19. Brewer E.J., Giannini E.H., Kuzmina N., Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the U.S.A.—U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 1986; 314:1269-1276
20. Giannini E.H., Brewer E.J., Kuzmina N., Alekseev L., Shokh B.P. Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis. Arthritis Rheum 1988; 31:15-20.
21. Giannini E.H., Brewer E.J. Jr., Kuzmina N., Shaikov A., Wallin B. Auranofin in the treatment of juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. Arthritis Rheum 1990; 33:466-476
22. Cassidy J.T., Levinson J.E., Bass J.C., et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29:274-281
23. Dolgopolova A.V., Bisiarina V.P., Alekseev L.S., Lepskaia E.S., Dmitrova N.A. Elaboration of the criteria for the early diagnosis of juvenile rheumatoid arthritis (JRA). Vopr Revm (Russian) 1979; 4:3-7.
24. Brewer E.J. Jr., Bass J., Baum J., et al. Current proposed revision of JRA criteria. Arthritis Rheum 1977; 20:Suppl: 195-9.
25. Brewer E.J. Jr., Giannini E.H. Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design. J Rheumatol 1982; 9:109-113
26. Paulus H.E., Egger M.J., Ward J.R., Williams H.J. Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33:477-484
27. Giannini E.H., Brewer E.J. Jr. Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data. J Rheumatol 1982; 9:114-122
28. Gehan E.A., Schneiderman M.A. Experimental design of clinical trials. In: Holland JF, Frei E III, eds. Cancer medicine, Philadelphia: Lea & Febiger, 1973:514.
29. Zar J.H. Biostatistical analysis. 2nd ed. Englewood Cliffs, N.J.: Prentice-Hall, 1984.
30. Furst D.E., Koehnke R., Burmeister L.F., Kohler J., Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16:313-320
31. Giannini E.H., Barron K.S., Spencer C.H., et al. Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial. J Rheumatol 1991; 18:1240-1242
32. Brewer E.J. Jr., Giannini E.H., Barkley E. Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis Rheum 1980; 23:404-411
33. Singh G., Athreya B., Fries J., Goldsmith D., Ostrov B. Measurement of functional status in juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33:Suppl:S15. abstract.
34. Howe S., Levinson J., Shear E., et al. Development of a disability measurement tool for juvenile rheumatoid arthritis: the Juvenile Arthritis Functional Assessment Report for Children and their Parents. Arthritis Rheum 1991; 34:873-880
35. Stewart C.F., Fleming R.A., Germain B.F., Seleznick M.J., Evans W.E. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 1991; 34:1514-1520
36. Kaplan M.M. Methotrexate hepatotoxic i ty and the premature reporting of Mark Twain#x0027;s death: both greatly exaggerated. Hepatology 1990; 12:784-786